Evidence map›Paper›PMID 40777082›Full record

ArticleFrontiers in cellular neuroscience2025

Investigation of early axonal phenotypes in an iPSC-derived ALS cellular model using a microfluidic device.

Asako Otomo, Keiko Nishijima, Yuta Murakami, Mitsuru Ishikawa, Haruka Yudahira, Kento Shimakura, Hideyuki Okano, Masashi Aoki, Hiroshi Kimura, Shinji Hadano

Abstract read
In one paragraph

Article in Frontiers in cellular neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Asako OtomoMolecular Neuropathobiology Laboratory, Department of Physiology, Tokai University School of Medicine, Isehara, Kanagawa, Japan.
Keiko NishijimaMolecular Neuropathobiology Laboratory, Department of Physiology, Tokai University School of Medicine, Isehara, Kanagawa, Japan.
Yuta MurakamiDepartment of Mechanical Engineering, Tokai University School of Engineering, Hiratsuka, Kanagawa, Japan.
Mitsuru IshikawaDivision of CNS Regeneration and Drug Discovery, International Center for Brain Science, Fujita Health University, Aichi, Japan.
Haruka YudahiraMolecular Neuropathobiology Laboratory, Department of Physiology, Tokai University School of Medicine, Isehara, Kanagawa, Japan.
Kento ShimakuraMolecular Neuropathobiology Laboratory, Department of Physiology, Tokai University School of Medicine, Isehara, Kanagawa, Japan.
Hideyuki OkanoDivision of CNS Regeneration and Drug Discovery, International Center for Brain Science, Fujita Health University, Aichi, Japan.
Masashi AokiDepartment of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Hiroshi KimuraMicro/Nano Technology Center, Tokai University, Hiratsuka, Kanagawa, Japan.
Shinji HadanoMolecular Neuropathobiology Laboratory, Department of Physiology, Tokai University School of Medicine, Isehara, Kanagawa, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease caused by the loss of upper and lower motor neurons. Mutations in the FUS/TLS gene have been reported as the second most common mutation in Japanese patients with familial ALS. In recent years, lower motor neurons (LMNs) differentiated from induced pluripotent stem cells (iPSCs) derived from ALS patients have been widely used to analyze the mechanisms of neuronal cell death and degeneration. Methods: In this study, we developed a microfluidic device designed to observe axonal growth, morphology, and trafficking at high resolution in neurons derived from induced pluripotent stem cells (iPSCs) and tested whether our microfluidic device effectively evaluates neurodegenerative phenotypes. We used iPSCs carrying homozygous FUS/TLS mutations (FUS_H517D) to induce LMNs by expressing NEUROG2, ISL1, and LHX3 under the control of the tetracycline regulation system. Results and discussions: After seven days of in vitro differentiation (DIV7), we confirmed that over 95% of iPSCs differentiated into HB9-positive LMNs. Notably, the cell viability of FUS_H517D LMNs was comparable to that of LMNs differentiated from iPSCs without the FUS/TLS mutation at DIV7. However, by DIV14 and DIV21, the viability of FUS_H517D LMNs was notably lower than that of control LMNs, indicating degeneration of FUS_H517D LMNs after differentiation. Using our microfluidic device, we assessed axonal phenotypes in FUS_H517D LMNs. Under oxidative stress conditions, we observed that the axonal length of FUS_H517D LMNs was significantly shorter than that of control cells as early as DIV7, with this axonal growth restriction becoming more pronounced by DIV11. This suggests that axonal growth restriction is an early detectable phenotype in degenerating neurons. Additionally, we examined mitochondrial trafficking within axons in our device, which is often disrupted in degenerative neurons. Our results showed a significant increase in the number of motile mitochondria in FUS_H517D LMNs, with retrograde transport accounting for a large portion of trafficking. Our microfluidic device-based culture and evaluation system using FUS_H517D LMNs offers a valuable ALS cellular model focused on early axonal phenotypes. This approach contributes to the study of molecular mechanisms underlying axonal degeneration in ALS.

Indexed as

amyotrophic lateral sclerosis (ALS)FUS/TLSiPSCslower motor neuronsmicrofluidic device

Identifiers

PMID40777082
PMCPMC12328293

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.